|
Basis of Presentation (Details) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 3 Months Ended | 3 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Mar. 31, 2014
Subsidiary in Venezuela
|
Mar. 31, 2013
Subsidiary in Venezuela
|
Dec. 31, 2013
Subsidiary in Venezuela
|
Dec. 31, 2013
Subsidiary in Venezuela
CADIVI
|
Feb. 11, 2013
Subsidiary in Venezuela
CADIVI
|
Mar. 31, 2014
Subsidiary in Venezuela
CADIVI
Medicinal products
|
Dec. 31, 2013
Subsidiary in Venezuela
CADIVI
Medicinal products
|
Mar. 31, 2014
Subsidiary in Venezuela
SICAD 1
|
Jan. 24, 2014
Subsidiary in Venezuela
SICAD 1
|
Dec. 31, 2013
Subsidiary in Venezuela
SICAD 1
|
Dec. 31, 2013
Subsidiary in Venezuela
SICAD 1
Other beneficial products
|
Jan. 24, 2014
Subsidiary in Venezuela
CENCOEX
|
Mar. 31, 2014
Subsidiary in Venezuela
SICAD 2
|
Mar. 31, 2014
Belarusian subsidiary
|
Mar. 31, 2013
Belarusian subsidiary
|
|
| Classification of Venezuela and Belarus as a Highly Inflationary Economy and Devaluation of Its Currencies | |||||||||||||||||||
| Exchange rate | 6.3 | 6.3 | 6.3 | 6.3 | 11.3 | 11.3 | 11.3 | 11.3 | 6.3 | 50.0 | |||||||||
| Foreign exchange loss from a re-measurement of assets and liabilities using official exchange rates | $ 845 | ||||||||||||||||||
| Net sales revenue as a percent of consolidated net sales revenue | 2.40% | 2.20% | 2.50% | 2.30% | |||||||||||||||
| Cash and cash equivalents | $ 71,467 | $ 77,247 | $ 83,036 | $ 79,241 | $ 2,585 | $ 3,922 | |||||||||||||